Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
出版年份 2021 全文链接
标题
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 2, Pages e001945
出版商
BMJ
发表日期
2021-02-10
DOI
10.1136/jitc-2020-001945
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
- (2020) Anita Gul et al. JOURNAL OF CLINICAL ONCOLOGY
- Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐ PD ‐1/ PD‐L1 agents?
- (2020) Michal Sternschuss et al. Thoracic Cancer
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA57Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)
- (2019) M-O Grimm et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
- (2017) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs
- (2013) Neil C Henderson et al. NATURE MEDICINE
- Pathogenesis of Liver Fibrosis
- (2011) Virginia Hernandez-Gea et al. Annual Review of Pathology-Mechanisms of Disease
- Hepatic stellate cells: Partners in crime for liver metastases?
- (2011) Ningling Kang et al. HEPATOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
- (2008) Scott L. Friedman PHYSIOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started